Thread Rating:
  • 0 Vote(s) - 0 Average
  • 1
  • 2
  • 3
  • 4
  • 5
GSK
#1
GSK posted some scary results in July, -16% revenue and flat to negative earnings, depending on which numbers you look at (income, profit, local currency vs exchange, etc). This decline was accomplished while apparently bribing doctors around the world to prescribe their products, which may have opened a whole other can of worms.

On the other hand, it does look like a tempting contrarian buy after the pullback, based on valuation and yield. They apparently have a strong pipeline aimed at 2016, which includes a diabetes drug (Tanzeum) which is my favorite pharmaceutical sector to invest in.

Thoughts?
Reply
#2
Doesnt the whole pharmaceutical industry do that? What started off as conspiracy theory, is now widely accepted as just the way the industry works. Drug companies "work" with doctors to "educate" people about the benefits and risks of the drugs.

They would probably get a slap on the wrist or something silly and the industry will continue operating the way it is.
Reply




Users browsing this thread: 1 Guest(s)